Recruitment

Recruitment Status
Completed
Estimated Enrollment
126

Inclusion Criteria

Able to provide written informed consent and to comply with all study procedures
More than total of 8 points on IPSS and 3 points on QoL
Symptoms of nocturia evidenced by ≥2 episodes per night in average according to 3-day voiding diary
...
Able to provide written informed consent and to comply with all study procedures
More than total of 8 points on IPSS and 3 points on QoL
Symptoms of nocturia evidenced by ≥2 episodes per night in average according to 3-day voiding diary
Males of at least 50 years of age, with current diagnosis of benign prostatic hyperplasia

Exclusion Criteria

Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data
Severe hepatic disorders or AST or ALT ≥ 3 x upper limit of normal (ULN)
Administration of following drugs within according periods prior to screening - 2 weeks: Antimuscarinic agents (Tolterodine, Trospium, Solifenacin, Fesoterodine, Propiverine, Oxybutynin, Flavoxate, etc), Anticholinesterase agents (Neostigmine methylsulfate, etc), Cholinergic agonists (Bethanechol Cl, etc), Benign prostatic hyperplasia agents (Tamsulosin HCl, Prazosin HCl, Terazosin HCl, Doxazosin mesylate, Silodosin, Naftopidil, etc), Tricyclic antidepressants (Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Quinupramine, etc), 6 months: 5-α-Reductase Inhibitors (Finasteride, Dutasteride)
...
Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data
Severe hepatic disorders or AST or ALT ≥ 3 x upper limit of normal (ULN)
Administration of following drugs within according periods prior to screening - 2 weeks: Antimuscarinic agents (Tolterodine, Trospium, Solifenacin, Fesoterodine, Propiverine, Oxybutynin, Flavoxate, etc), Anticholinesterase agents (Neostigmine methylsulfate, etc), Cholinergic agonists (Bethanechol Cl, etc), Benign prostatic hyperplasia agents (Tamsulosin HCl, Prazosin HCl, Terazosin HCl, Doxazosin mesylate, Silodosin, Naftopidil, etc), Tricyclic antidepressants (Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Quinupramine, etc), 6 months: 5-α-Reductase Inhibitors (Finasteride, Dutasteride)
Alcoholism or sustained drug dependent abuse 1 year prior to screening
Severe cardiac disorders or development or diagnosis of vascular disorder (unstable angina, myocardial infarction, cerebral infarction, cerebral hemorrhage, coronary artery bypass graft, etc) 6 months prior to enrollment
Symptoms of postural hypotension
History of acute urinary retention
History of prostatic surgery
Patients with neurogenic bladder
History of prostatic cancer
Patients with bladder cancer, cystolith or urethral stricture
Patients with pyuria 1 month prior to screening
Hypersensitivity to α1A-receptor blockers
Patients with uncontrolled chronic disease
Severe renal disorders or creatinine clearance ≥ 2.0 mg/dL
PSA level > 10 ng/㎖ (except patients who had 4 ng/㎖ < PSA level ≤ 10 ng/㎖ 6 months prior to screening and identified as negative from biopsy)
Indwelling catheter or self intermittent catheterization
Any disorder of the gastrointestinal system which could result in altered digestion or absorption, history of gastrointestinal tract surgery except ecphyadectomy

Summary

Conditions
  • Benign Prostatic Hyperplasia
  • Nocturia
Type
Interventional
Phase
Phase 4
Design
  • Allocation: N/A
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 50 years and 125 years
Gender
Only males

Description

This study is designed as a multi-center, prospective, open-label and single-arm study. Subjects who are willing to provide written informed consent will be enrolled after screening for eligibility criteria. The subjects will be administered with investigational product for 12 weeks and visit as out...

This study is designed as a multi-center, prospective, open-label and single-arm study. Subjects who are willing to provide written informed consent will be enrolled after screening for eligibility criteria. The subjects will be administered with investigational product for 12 weeks and visit as outpatients for evaluation of safety and efficacy at baseline (visit 2) and 4 weeks (visit 3) and 12 weeks (visit 4) after baseline.

Inclusion Criteria

Able to provide written informed consent and to comply with all study procedures
More than total of 8 points on IPSS and 3 points on QoL
Symptoms of nocturia evidenced by ≥2 episodes per night in average according to 3-day voiding diary
...
Able to provide written informed consent and to comply with all study procedures
More than total of 8 points on IPSS and 3 points on QoL
Symptoms of nocturia evidenced by ≥2 episodes per night in average according to 3-day voiding diary
Males of at least 50 years of age, with current diagnosis of benign prostatic hyperplasia

Exclusion Criteria

Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data
Severe hepatic disorders or AST or ALT ≥ 3 x upper limit of normal (ULN)
Administration of following drugs within according periods prior to screening - 2 weeks: Antimuscarinic agents (Tolterodine, Trospium, Solifenacin, Fesoterodine, Propiverine, Oxybutynin, Flavoxate, etc), Anticholinesterase agents (Neostigmine methylsulfate, etc), Cholinergic agonists (Bethanechol Cl, etc), Benign prostatic hyperplasia agents (Tamsulosin HCl, Prazosin HCl, Terazosin HCl, Doxazosin mesylate, Silodosin, Naftopidil, etc), Tricyclic antidepressants (Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Quinupramine, etc), 6 months: 5-α-Reductase Inhibitors (Finasteride, Dutasteride)
...
Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data
Severe hepatic disorders or AST or ALT ≥ 3 x upper limit of normal (ULN)
Administration of following drugs within according periods prior to screening - 2 weeks: Antimuscarinic agents (Tolterodine, Trospium, Solifenacin, Fesoterodine, Propiverine, Oxybutynin, Flavoxate, etc), Anticholinesterase agents (Neostigmine methylsulfate, etc), Cholinergic agonists (Bethanechol Cl, etc), Benign prostatic hyperplasia agents (Tamsulosin HCl, Prazosin HCl, Terazosin HCl, Doxazosin mesylate, Silodosin, Naftopidil, etc), Tricyclic antidepressants (Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Quinupramine, etc), 6 months: 5-α-Reductase Inhibitors (Finasteride, Dutasteride)
Alcoholism or sustained drug dependent abuse 1 year prior to screening
Severe cardiac disorders or development or diagnosis of vascular disorder (unstable angina, myocardial infarction, cerebral infarction, cerebral hemorrhage, coronary artery bypass graft, etc) 6 months prior to enrollment
Symptoms of postural hypotension
History of acute urinary retention
History of prostatic surgery
Patients with neurogenic bladder
History of prostatic cancer
Patients with bladder cancer, cystolith or urethral stricture
Patients with pyuria 1 month prior to screening
Hypersensitivity to α1A-receptor blockers
Patients with uncontrolled chronic disease
Severe renal disorders or creatinine clearance ≥ 2.0 mg/dL
PSA level > 10 ng/㎖ (except patients who had 4 ng/㎖ < PSA level ≤ 10 ng/㎖ 6 months prior to screening and identified as negative from biopsy)
Indwelling catheter or self intermittent catheterization
Any disorder of the gastrointestinal system which could result in altered digestion or absorption, history of gastrointestinal tract surgery except ecphyadectomy

Locations

Busan, 602-739
Seoul, 133-792
Suwon, Gyeonggi-do, 443-380
Seoul, 140-887
Bucheon, Gyeonggi-do, 420-818
...
Busan, 602-739
Seoul, 133-792
Suwon, Gyeonggi-do, 443-380
Seoul, 140-887
Bucheon, Gyeonggi-do, 420-818
Daejeon, 302-799

Tracking Information

NCT #
NCT02106182
Collaborators
Not Provided
Investigators
Not Provided